Sam-A Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Sam-A Pharm makes prescription and over-the-counter medicines, including respiratory treatments, antibiotics, skin-care drugs, digestive aids, and fever-and-pain relievers, for patients in South Korea.
It supplies these products to hospitals, clinics, and wholesale distributors through offices across Seoul and regional cities. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company earns the large majority of its revenue from its respiratory medicine line.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates a dedicated manufacturing plant certified under Korea's Good Manufacturing Practice standard, capable of producing solid-dose, liquid, topical, and health-supplement products.
Sam-A Pharm in five facts
What does Sam-A Pharm do?
Sam-A Pharm makes prescription and over-the-counter medicines, including respiratory treatments, antibiotics, skin-care drugs, digestive aids, and fever-and-pain relievers, for patients in South Korea.
Where is Sam-A Pharm listed and in which sector?
Sam-A Pharm (Korean name: 삼아제약) trades under KRX code 009300 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Sam-A Pharm?
Its market capitalisation was US$65.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Sam-A Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Sam-A Pharm reported revenue of US$58.7M, operating profit of US$8.3M and net income of US$9.8M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 18.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
Sam-A Pharm declared a cash dividend of US$0.60 per share.
Dividend · Feb 26 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Sam-A Pharm reported consolidated results for FY2025: revenue of US$54.5M (−18.6% year on year), operating profit of US$7.69M (−55.1% year on year) and net income of US$9.07M (−41.4% year on year).
Earnings · Feb 26